Get the Stockscreener App
5.55
4.91%
0.26
Corvus Pharmaceuticals Inc stock is traded at $5.55, with a volume of 618.13K.
It is up +4.91% in the last 24 hours and up +28.18% over the past month.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).
See More
Previous Close:
$5.29
Open:
$5.32
24h Volume:
618.13K
Relative Volume:
0.84
Market Cap:
$413.55M
Revenue:
-
Net Income/Loss:
$-27.03M
P/E Ratio:
-9.9107
EPS:
-0.56
Net Cash Flow:
$-23.97M
1W Performance:
+2.21%
1M Performance:
+28.18%
6M Performance:
+32.46%
1Y Performance:
+33.73%
1-Day Range:
$5.22
$5.635
1-Week Range:
$5.03
$5.81
52-Week Range:
$2.54
$10.00
Corvus Pharmaceuticals Inc Stock (CRVS) Company Profile
Name
Corvus Pharmaceuticals Inc
Sector
Industry
Phone
(650) 900-4520
Address
863 MITTEN ROAD, BURLINGAME, CA
Compare CRVS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CRVS
Corvus Pharmaceuticals Inc
|
5.55 | 396.41M | 0 | -27.03M | -23.97M | -0.56 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Corvus Pharmaceuticals Inc Stock (CRVS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-02-25 | Initiated | H.C. Wainwright | Buy |
| Aug-18-23 | Initiated | Oppenheimer | Outperform |
| Dec-01-21 | Resumed | Jefferies | Buy |
| May-27-21 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-10-21 | Downgrade | Mizuho | Buy → Neutral |
| Sep-12-19 | Initiated | Mizuho | Buy |
| May-29-19 | Initiated | ROTH Capital | Buy |
| Aug-24-17 | Upgrade | Credit Suisse | Underperform → Neutral |
| May-01-17 | Downgrade | Credit Suisse | Neutral → Underperform |
| Apr-18-16 | Initiated | Credit Suisse | Outperform |
| Apr-18-16 | Initiated | Guggenheim | Buy |
View All
Corvus Pharmaceuticals Inc Stock (CRVS) Latest News
Price momentum metrics for Corvus Pharmaceuticals Inc. explainedWeekly Profit Analysis & Technical Pattern Recognition Alerts - Newser
Is Corvus Pharmaceuticals Inc. the Top Chart Pick This WeekJuly 2025 Reactions & Verified Short-Term Trading Plans - newsyoung.net
Pattern recognition hints at Corvus Pharmaceuticals Inc. upsideEarnings Overview Summary & Fast Momentum Stock Entry Tips - Newser
Corvus Pharmaceuticals Inc. stock volume spike explained2025 Technical Patterns & Entry and Exit Point Strategies - Newser
How to read the order book for Corvus Pharmaceuticals Inc.Market Trend Report & Capital Efficiency Focused Strategies - Newser
Can volume confirm reversal in Corvus Pharmaceuticals Inc.2025 Investor Takeaways & Daily Stock Trend Watchlist - Newser
Custom strategy builders for tracking Corvus Pharmaceuticals Inc.July 2025 Summary & Daily Technical Stock Forecast Reports - Newser
Analyzing recovery setups for Corvus Pharmaceuticals Inc. investors2025 Biggest Moves & Long-Term Investment Growth Plans - Newser
Will Corvus Pharmaceuticals Inc. benefit from macro trendsQuarterly Profit Report & Free Weekly Watchlist of Top Performers - Newser
Comparing Corvus Pharmaceuticals Inc. in custom built stock radarsLong Setup & Weekly High Return Stock Opportunities - Newser
Corvus Pharmaceuticals Inc. stock trend forecastJuly 2025 EndofMonth & Long-Term Safe Investment Ideas - Newser
Is Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Trading At A 49% Discount? - simplywall.st
Is this a good reentry point in Corvus Pharmaceuticals Inc.July 2025 Market Mood & Verified Technical Trade Signals - Newser
Is Corvus Pharmaceuticals Inc. stock entering bullish territoryJuly 2025 Opening Moves & Real-Time Market Sentiment Alerts - Newser
What to expect from Corvus Pharmaceuticals Inc. in the next 30 daysJuly 2025 Recap & Daily Price Action Insights - Newser
How to forecast Corvus Pharmaceuticals Inc. trends using time seriesTrade Exit Report & Fast Exit Strategy with Risk Control - Newser
Is Corvus Pharmaceuticals Inc. Stock a Smart Buy in 2025 Investment Analysis Inside - Newser
Sentiment analysis tools applied to Corvus Pharmaceuticals Inc.July 2025 EndofMonth & Reliable Trade Execution Plans - Newser
Real time pattern detection on Corvus Pharmaceuticals Inc. stockEarnings Beat & Target Return Focused Picks - Newser
Live market analysis of Corvus Pharmaceuticals Inc.Rate Cut & Safe Capital Growth Stock Tips - Newser
Price action breakdown for Corvus Pharmaceuticals Inc.July 2025 Fed Impact & Safe Investment Capital Preservation Plans - Newser
Can swing trading help recover from Corvus Pharmaceuticals Inc. losses2025 Market Outlook & Stepwise Entry and Exit Trade Signals - Newser
Corvus Pharmaceuticals’ Earnings Call Highlights Progress - MSN
Is now a turning point for Corvus Pharmaceuticals Inc.2025 Year in Review & Risk Managed Investment Entry Signals - Newser
New Product Launches: Will They Boost Corvus Pharmaceuticals Inc. Stock in 2025July 2025 Intraday Action & Daily Profit Focused Screening - Newser
Advanced analytics toolkit walkthrough for Corvus Pharmaceuticals Inc.2025 Macro Impact & Free Daily Entry Point Trade Alerts - Newser
What makes Corvus Pharmaceuticals Inc. stock price move sharplyJuly 2025 Volume & Daily Growth Stock Tips - Newser
Is Corvus Pharmaceuticals Inc. in a long term uptrendJuly 2025 Action & Consistent Profit Focused Trading Strategies - thegnnews.com
Corvus (CRVS) Q2 Loss Beats Estimates - AOL.com
A Tale of Resilience: Corvus Pharmaceuticals Inc Amid Stock Market Turbulence - investchronicle.com
How Resilient Is Corvus Pharmaceuticals Inc. Stock During Economic DownturnsEarnings Risk Report & High Yield Stock Recommendations - Newser
Corvus Pharmaceuticals Inc Stock (CRVS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Corvus Pharmaceuticals Inc Stock (CRVS) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Thompson Peter A. | Director |
Jun 27 '25 |
Sale |
4.16 |
1,176,332 |
4,891,894 |
7,165,006 |
| Jones William Benton | See Remarks |
Jun 04 '25 |
Option Exercise |
3.50 |
19,357 |
67,750 |
173,130 |
| MILLER RICHARD A MD | President and CEO |
May 07 '25 |
Option Exercise |
3.50 |
559,073 |
1,956,756 |
1,136,707 |
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):